U.S. drug regulators on Feb. 11 announced they are pushing back a decision on Pfizer’s COVID-19 vaccine for children as young as 6 months old. The Food and Drug Administration (FDA) had planned to consult its vaccine advisory committee on Feb. 15 on whether to clear the jab for young children, but changed that plan based on a preliminary assessment of Pfizer sent on Feb. 1. Pfizer was seeking emergency use authorization (EUA) for its two-dose primary regimen for children aged 6 months to 4 years but, citing the assessment, “we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization,” Dr. Janet Woodcock and Dr. Peter Marks, two top FDA officials, said in a joint statement. Delaying the meeting and the decision “will give the agency time to consider the additional data, allowing for a transparent public …